Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14954265 | 0.89 | PTPN1 (0.68) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL27780036 | 0.86 | LCK (0.56) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL12497067 | 0.86 | LCK (0.56) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL29597330 | 0.84 | LCK (0.46) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL21635979 | 0.84 | KDM4E (0.65) | PTPN1SMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL28257934 | 0.84 | PTPN1 (0.57) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL27851655 | 0.83 | HSD17B10 (0.62) | LCKFYNPTPN1PKMMAPT | |
| SCHEMBL1438926 | 0.82 | PKM (0.62) | LCKFYNPTPN1PKMMAPT | |
| SCHEMBL437132 | 0.82 | LCK (0.56) | LCKFYNPTPN1PKMSMN1; SMN2 | |
| SCHEMBL30740970 | 0.82 | LCK (0.56) | LCKFYNPTPN1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923007-A | Acridine compound and application thereof | UNIV DALIAN TECH | 2014-07-16 | — | — | CN | claimed |
| JP-5078299-A | — | — | None | — | — | JP | disclosed |
| US-12577213-B2 | Deuterated 1,4-benzodiazepine-2,5-dione compound and use thereof | Ningbo Combireg Pharmaceutical Technology Co., Ltd. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20240131001-A1 | PHARMACEUTICAL APPLICATION OF FUSED RING PHENOLIC COMPOUNDS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240002353-A1 | DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF | Ningbo Combireg Pharmaceutical Technology Co., Ltd. (CN) | 2024-01-04 | — | — | US | disclosed |
| CN-114507190-B | Deuterated 1, 4-benzodiazepine-2, 5-diketone compound and application thereof | 宁波康柏睿格医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4260854-A1 | PHARMACEUTICAL APPLICATION OF FUSED-RING PHENOLIC COMPOUND | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4249473-A1 | DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF | Ningbo Combireg Pharmaceutical Technology Co., Ltd (CN) | 2023-09-27 | — | — | EP | disclosed |
| CN-116568297-A | Pharmaceutical use of fused ring phenolic compounds | 润佳（苏州）医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-5073448-A | Containing light stabilizers | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0144396-B1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | VAN'T RIET, Bartholomeus (US) | 1991-01-02 | — | — | EP | disclosed |
| US-4942253-A | INHIBITORS OF RIBONUCLEOTIDE REDUCTASE, ANTITUMOR AGENTS, LEUKEMIA, FREE RADICAL SCAVENGERS | RIET BARTHOLOMEUS VAN T (US) | 1990-07-17 | — | — | US | disclosed |
| EP-0181526-B1 | BENZOIC ACID DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1989-01-18 | — | — | EP | disclosed |
| US-4698364-A | INFECTION CONTROL | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-10-06 | — | — | US | disclosed |
| US-4623659-A | RIBONUCLEOTIDE REDUCTASE INHIBITORS | RIET BARTHOLOMEUS VAN T (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0144396-A4 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1986-08-21 | — | — | EP | disclosed |
| EP-0181526-A1 | Benzoic acid derivatives | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-05-21 | — | — | EP | disclosed |
| EP-0144396-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES. | RIET BARTHOLOMEUS VAN T (US) | 1985-06-19 | — | — | EP | disclosed |
| WO-1984004676-A1 | POLYHYDROXYBENZOIC ACID DERIVATIVES | RIET BARTHOLOMEUS VAN T | 1984-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002353-A1 | DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | LCK 4842/4885FYN 4221/4885PTPN1 3315/4885 |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | LCK 2557/4885FYN 1172/4885PTPN1 2603/4885 |
| US-20240131001-A1 | PHARMACEUTICAL APPLICATION OF FUSED RING PHENOLIC COMPOUNDS | PCK1, PDPK1, IPMK | LCK 377/4885FYN 893/4885PTPN1 600/4885 |
| US-12577213-B2 | Deuterated 1,4-benzodiazepine-2,5-dione compound and use thereof | HSD3B1, CYP11B1, CYP2E1 | LCK 4798/4885FYN 4407/4885PTPN1 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.